9 results  1 of 1 

1 Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
Min Hwan Kim, Xianglan Zhang, Minkyu Jung, Inkyung Jung, Hyung Soon Park, Seung-Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyunki Kim, Yoon Young Choi, Taeil Son, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung
Cancer Res Treat.2019;51(2):819-831.   Published online 2018 September 27     DOI: http://dx.doi.org/10.4143/crt.2018.331
      
2 ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
Ji-Youn Han, Geon Kook Lee, Kun Young Lim, Young Ju Lee, Byung Ho Nam, Jin Soo Lee
Cancer Res Treat.2017;49(3):678-687.   Published online 2016 October 11     DOI: http://dx.doi.org/10.4143/crt.2016.365
      
3 Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
Jae Joon Han, Sun Kyung Baek, Jae Jin Lee, Gou Young Kim, Si-Young Kim, Suk-Hwan Lee
Cancer Res Treat.2014;46(1):55-64.   Published online 2014 January 15     DOI: http://dx.doi.org/10.4143/crt.2014.46.1.55
      
4 ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma
Kyun Woo Park, Eun-Seon Jung, Dong-Gu Kim, Young-Kyung Yoo, Tae-Ho Hong, In Seok Lee, Yoon Ho Koh, Ji-Hoon Kim, Myung Ah Lee
Cancer Res Treat.2013;45(1):63-69.   Published online 2013 March 31     DOI: http://dx.doi.org/10.4143/crt.2013.45.1.63
      
5 The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes
Dokyung Kim, Woohee Jung, Ja Seung Koo
J Korean Med Sci.2011;26(3):352-359.   Published online 2011 February 25     DOI: http://dx.doi.org/10.3346/jkms.2011.26.3.352
      
6 Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
Jina Yun, Kyoung-Mee Kim, Seung Tae Kim, Jung-Hoon Kim, Jung A Kim, Jee Hyun Kong, Soo Hyeon Lee, Young-Woong Won, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat.2010;42(2):101-106.   Published online 2010 June 30     DOI: http://dx.doi.org/10.4143/crt.2010.42.2.101
      
7 Chemotherapeutic Responsibility according to Polymorphism of ERCC1, XRCC1 and GSTP1 in Gastric Cancer Patients Receiving Oxaliplatin Based Chemotherapy
Dae Youn Won, Soo Hong Kim, Hoon Hur, Hun Jung, Hae Myung Jeon
J Korean Surg Soc.2010;78(6):350-356.   Published online 2010 June 7     DOI: http://dx.doi.org/10.4174/jkss.2010.78.6.350
      
8 Relation between ERCC1 Expression in Sputum and Survival after Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
Sung Woo Yang, Pyoung Rak Choi, Hong Jun You, Jin Gu Kim, Chul Ho Oak, Tae Won Jang, Maan Hong Jung
Tuberc Respir Dis.2006;60(2):151-159.   Published online 2006 February 28     DOI: http://dx.doi.org/10.4046/trd.2006.60.2.151
      
9 Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric Cancer
Sun Kyung Baek, Si-Young Kim, Jae Jin Lee, Yoon Wha Kim, Hwi Joong Yoon, Kyung Sam Cho
Cancer Res Treat.2006;38(1):19-24.   Published online 2006 February 28     DOI: http://dx.doi.org/10.4143/crt.2006.38.1.19
      

 1 of 1